BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16524383)

  • 21. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro.
    Hirohata M; Ono K; Naiki H; Yamada M
    Neuropharmacology; 2005 Dec; 49(7):1088-99. PubMed ID: 16125740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrillogenic and non-fibrillogenic ensembles of SDS-bound human alpha-synuclein.
    Ahmad MF; Ramakrishna T; Raman B; Rao ChM
    J Mol Biol; 2006 Dec; 364(5):1061-72. PubMed ID: 17054982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds.
    Caruana M; Högen T; Levin J; Hillmer A; Giese A; Vassallo N
    FEBS Lett; 2011 Apr; 585(8):1113-20. PubMed ID: 21443877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood-borne factors inhibit Alzheimer's beta-amyloid fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Samuraki M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M
    Exp Neurol; 2006 Nov; 202(1):125-32. PubMed ID: 16806179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro.
    Morinaga A; Hirohata M; Ono K; Yamada M
    Biochem Biophys Res Commun; 2007 Aug; 359(3):697-702. PubMed ID: 17559807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of antiparkinsonian agents on β-amyloid and α-synuclein oligomer formation in vitro.
    Ono K; Takasaki J; Takahashi R; Ikeda T; Yamada M
    J Neurosci Res; 2013 Oct; 91(10):1371-81. PubMed ID: 23913715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-amyloidogenic activity of S-allyl-L-cysteine and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro.
    Gupta VB; Rao KS
    Neurosci Lett; 2007 Dec; 429(2-3):75-80. PubMed ID: 18023978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of docosahexaenoic acid-induced inhibition of in vitro Abeta1-42 fibrillation and Abeta1-42-induced toxicity in SH-S5Y5 cells.
    Hossain S; Hashimoto M; Katakura M; Miwa K; Shimada T; Shido O
    J Neurochem; 2009 Oct; 111(2):568-79. PubMed ID: 19686246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro evidence that an aqueous extract of Centella asiatica modulates α-synuclein aggregation dynamics.
    Berrocal R; Vasudevaraju P; Indi SS; Sambasiva Rao KR; Rao KS
    J Alzheimers Dis; 2014; 39(2):457-65. PubMed ID: 24284367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein.
    Kim YS; Lim D; Kim JY; Kang SJ; Kim YH; Im H
    Biochem Biophys Res Commun; 2009 Oct; 387(4):682-7. PubMed ID: 19622344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of fibrillation process of alpha-synuclein at the initial stage.
    Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
    Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
    Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization.
    Bosco DA; Fowler DM; Zhang Q; Nieva J; Powers ET; Wentworth P; Lerner RA; Kelly JW
    Nat Chem Biol; 2006 May; 2(5):249-53. PubMed ID: 16565714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of saffron and its constituents, crocin-1, crocin-2, and crocetin on α-synuclein fibrils.
    Inoue E; Shimizu Y; Masui R; Hayakawa T; Tsubonoya T; Hori S; Sudoh K
    J Nat Med; 2018 Jan; 72(1):274-279. PubMed ID: 29147836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure.
    Hirohata M; Hasegawa K; Tsutsumi-Yasuhara S; Ohhashi Y; Ookoshi T; Ono K; Yamada M; Naiki H
    Biochemistry; 2007 Feb; 46(7):1888-99. PubMed ID: 17253770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin inhibits aggregation of alpha-synuclein.
    Pandey N; Strider J; Nolan WC; Yan SX; Galvin JE
    Acta Neuropathol; 2008 Apr; 115(4):479-89. PubMed ID: 18189141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein.
    Kobayashi M; Kim J; Kobayashi N; Han S; Nakamura C; Ikebukuro K; Sode K
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1139-44. PubMed ID: 16962995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis.
    Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S
    Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.